Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation
暂无分享,去创建一个
[1] H. Katus,et al. DYRK1A Is a Novel Negative Regulator of Cardiomyocyte Hypertrophy* , 2009, The Journal of Biological Chemistry.
[2] Paul Antoine Salin,et al. DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome. , 2009, Human molecular genetics.
[3] Min-Su Jung,et al. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[4] Desmond J. Smith,et al. Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A , 2009, PloS one.
[5] Tao Liu,et al. Parallel RNAi screens across different cell lines identify generic and cell type-specific regulators of actin organization and cell morphology , 2009, Genome Biology.
[6] J. Delabar,et al. The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. , 2008, Developmental cell.
[7] B. Lutz,et al. The down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4 , 2008, Neuroscience.
[8] P. Clarke,et al. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine , 2008, The FEBS journal.
[9] Xavier Estivill,et al. DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. , 2008, American journal of human genetics.
[10] J. Wegiel,et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] J. Wegiel,et al. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome , 2008, Acta Neuropathologica.
[12] S. Sang,et al. Bioavailability issues in studying the health effects of plant polyphenolic compounds. , 2008, Molecular nutrition & food research.
[13] Reinhard Ullmann,et al. Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. , 2008, American journal of human genetics.
[14] F. Tejedor,et al. The spatio‐temporal and subcellular expression of the candidate Down syndrome gene Mnb/Dyrk1A in the developing mouse brain suggests distinct sequential roles in neuronal development , 2008, The European journal of neuroscience.
[15] Hyun-Jeong Cho,et al. Dual‐specificity tyrosine(Y)‐phosphorylation regulated kinase 1A‐mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease , 2008, Journal of neurochemistry.
[16] W. Wisden,et al. Hammerle B., Elizalde C., Tejedor FJ.(2008) The Spatio-Temporal and subcellular Expression of the Candidate Down Syndrome Gene Mnb/Dyrk1A in the Developing Mouse Brain Suggests Distinct Sequential Roles in Neuronal Development. Eur. J. Neurosci. 27:1061-1074 (F.I.: 3.673 ) , 2008 .
[17] P. Cohen,et al. The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.
[18] K. Chung,et al. Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome , 2007, Molecular and Cellular Neuroscience.
[19] Y. Hwang,et al. Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro. , 2007, Biochemistry.
[20] R. Damoiseaux,et al. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. , 2007, Cell metabolism.
[21] T. Iwatsubo,et al. Dyrk1A Phosphorylates α-Synuclein and Enhances Intracellular Inclusion Formation* , 2006, Journal of Biological Chemistry.
[22] Jung Tae Lee,et al. Putative therapeutic agents for the learning and memory deficits of people with Down syndrome. , 2006, Bioorganic & medicinal chemistry letters.
[23] M. Dierssen,et al. DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis , 2006, TheScientificWorldJournal.
[24] Xin Gao,et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.
[25] T. Iwatsubo,et al. Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation. , 2006, The Journal of biological chemistry.
[26] W. Becker,et al. The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site , 2006, BMC Biochemistry.
[27] I. Ferrer,et al. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models , 2005, Neurobiology of Disease.
[28] G. Elston,et al. Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/− mouse , 2005, Neurobiology of Disease.
[29] P. Kelly,et al. DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. , 2005, Molecular biology of the cell.
[30] Takuya Ueda,et al. Protein synthesis by pure translation systems. , 2005, Methods.
[31] P. Lochhead,et al. Activation-Loop Autophosphorylation Is Mediated by a Novel Transitional Intermediate Form of DYRKs , 2005, Cell.
[32] E. Rubin,et al. Transgenic Mouse In Vivo Library of Human Down Syndrome Critical Region 1: Association between DYRK1A Overexpression, Brain Development Abnormalities, and Cell Cycle Protein Alteration , 2004, Journal of neuropathology and experimental neurology.
[33] Jian Wang,et al. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine. , 2004, Biochemical and biophysical research communications.
[34] Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. , 2003, The Journal of nutrition.
[35] D. Morrison,et al. dDYRK2: a novel dual-specificity tyrosine-phosphorylation-regulated kinase in Drosophila. , 2003, The Biochemical journal.
[36] J. Cerón,et al. Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation , 2003, The European journal of neuroscience.
[37] P. Cohen,et al. The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.
[38] J. Galceran,et al. The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications. , 2003, Journal of neural transmission. Supplementum.
[39] K. Chung,et al. Protein Kinase Dyrk1 Activates cAMP Response Element-binding Protein during Neuronal Differentiation in Hippocampal Progenitor Cells* , 2001, The Journal of Biological Chemistry.
[40] T. Blundell,et al. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. , 2001, The Biochemical journal.
[41] R. Poland,et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. , 1999, Journal of ethnopharmacology.
[42] X. Estivill,et al. Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases. , 1999, Biochemical and biophysical research communications.
[43] H. Joost,et al. Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases* , 1998, The Journal of Biological Chemistry.
[44] R. Ramsay,et al. Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .
[45] R. Ramsay,et al. Inhibition of monoamine oxidase A by beta-carboline derivatives. , 1997, Archives of biochemistry and biophysics.
[46] M Heisenberg,et al. minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila , 1995, Neuron.